Publication date: May 13, 2026
In particular, the evidence of dose-dependent slowing of progression on the cUHDRS disease rating scale in the Stage 2 study participants supports the Novartis-initiated Phase 3 INVEST-HD study. We look forward to continuing to review the data and aligning on potential regulatory interactions based on the results with our partner Novartis.
| Concepts | Keywords |
|---|---|
| Ceo | Clinical |
| Huntingtons | Dose |
| Nfl | Hd |
| Proteinhuntingtons | Huntingtons |
| Yearlong | Novartis |
| Participants | |
| Phase | |
| Placebo | |
| Progression | |
| Ptc | |
| Slowing | |
| Stage | |
| Study | |
| Trial | |
| Votoplam |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Tropicamide |
| drug | DRUGBANK | Methionine |
| disease | MESH | disease progression |
| disease | MESH | PTC |
| pathway | REACTOME | Release |
(Visited 9 times, 1 visits today)